NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
Estimated value
—
goods
Awarded value
—
Suppliers
24
6 SME
Lots
2
0 awarded
Published
29 Jul 2025
Description
NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025<br/>CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 <br/>CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026
Scope
- Reference
- CM/PHR/24/5680
- Commercial tool
- Standalone contract
- Contract dates
- 31 Aug 2025 to 31 Aug 2027
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- UK
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| — | — | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 24 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Awarded to
BI
Lots · 2 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | Lot 1 - CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East | £2.8bn | cancelled |
| 2 | Lot 2 - CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE | £26.4m | cancelled |